Literature DB >> 32784295

Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia.

Jui-Feng Chang1, Huei-Chun Liu1, H H Chen1, Wen-Ping Chen2, Jian-Lin Juang3, Pei-Ning Wang4,5,6, Shieh-Yueh Yang7,8.   

Abstract

BACKGROUND: The stability of proteins in the collecting tubes after blood draw is critical to the measured concentrations of the proteins. Although the guidelines issued by the Clinical and Laboratory Standards Institute (CLSI) suggest centrifugation should take place within 2 h of drawing blood, it is very difficult to follow these guidelines in hospitals or clinics. It is necessary to study the effect of times to blood processing on the stability of the proteins of interest.
METHODS: In this work, the plasma proteins of interest were those relevant to dementia, such as amyloid β 1-40 (Aβ1-40), Aβ1-42, Tau protein (Tau), and α-synuclein. The times to blood processing after blood draw ranged from 0.5 to 8 h. The storage temperatures of blood were room temperature (approx. 25°C) and 30°C. After storage, blood samples were centrifuged at room temperature to obtain plasma samples. Ultrasensitive immunomagnetic reduction was applied to assay these proteins in the plasma.
RESULTS: The levels of plasma Aβ1-40, Tau, and α-synuclein did not significantly change until 8 h after blood draw when stored at room temperature. Plasma Aβ1-42 levels did not change significantly after 8 h of storage at room temperature before blood processing. Higher storage temperatures, such as 30°C, for blood samples accelerated the significant variations in the measured concentrations of Aβ1-40, Tau, and α-synuclein in plasma.
CONCLUSION: According to these results, for clinical practice, it is suggested that blood samples be stored at room temperature for no longer than 4.5 h after blood draw until centrifugation for the assay of dementia biomarkers in plasma.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Blood; Centrifugation; Dementia; Immunomagnetic reduction; Stability

Mesh:

Substances:

Year:  2020        PMID: 32784295     DOI: 10.1159/000509358

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  2 in total

1.  Assessment of High Risk for Alzheimer's Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan: A Preliminary Study.

Authors:  Chaur-Jong Hu; Ming-Jang Chiu; Ming-Chyi Pai; Sui-Hing Yan; Pei-Ning Wang; Pai-Yi Chiu; Chin-Hsien Lin; Ta-Fu Chen; Fu-Chi Yang; Kuo-Lun Huang; Yi-Ting Hsu; Yi-Chou Hou; Wei-Che Lin; Cheng-Hsien Lu; Li-Kai Huang; Shieh-Yueh Yang
Journal:  J Alzheimers Dis Rep       Date:  2021-10-21

2.  Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.

Authors:  Inge M W Verberk; Els O Misdorp; Jannet Koelewijn; Andrew J Ball; Kaj Blennow; Jeffrey L Dage; Noelia Fandos; Oskar Hansson; Christophe Hirtz; Shorena Janelidze; Sungmin Kang; Kristopher Kirmess; Jana Kindermans; Ryan Lee; Matthew R Meyer; Dandan Shan; Leslie M Shaw; Teresa Waligorska; Tim West; Henrik Zetterberg; Rebecca M Edelmayer; Charlotte E Teunissen
Journal:  Alzheimers Dement       Date:  2021-11-29       Impact factor: 16.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.